Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.

Détails

Ressource 1Télécharger: PPA-377780-medication-adherence-evaluated-through-electronic-monitors-d.pdf (1051.59 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_813F43A545D0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Périodique
Patient preference and adherence
Auteur⸱e⸱s
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C., Zanchi A., Cavassini M., Schneider M.P.
ISSN
1177-889X (Print)
ISSN-L
1177-889X
Statut éditorial
Publié
Date de publication
2022
Peer-reviewed
Oui
Volume
16
Pages
2313-2320
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
During the 2020 COVID-19 lockdown, patients included in the Interprofessional Medication Adherence Program (IMAP) in Switzerland continued to use electronic monitors (EMs) that registered daily drug-dose intake. We aimed to understand to what extent patients' medication implementation (ie, the extent to which the patient took the prescribed medicine), measured with EMs, was impacted by the lockdown.
Patients participating in the IMAP were diagnosed with diabetic kidney disease (DKD), solid cancer, human immunodeficiency virus (HIV) and miscellaneous long-term diseases (MLTD). Patient implementation was defined through a proxy: if all patient EMs were opened at least once daily, implementation was considered active (=1), and no implementation was considered (=0) otherwise. Implementation before (from December 2019 to March 2020), during (March to June 2020) and after (June to September 2020) the lockdown was compared. Subanalyses were performed according to the patients' diseases. Subanalyses were performed in patients who used at least one EM in 2018-2019 during the same periods (defined as winter, spring and summer). The logistic regression models used to estimate medication implementation according to the period were fitted using generalized estimating equations.
In 2020, patient implementation (n = 118) did not differ significantly before versus during (OR = 0.98, 95% CI: 0.84-1.15, p = 0.789) and before versus after (OR = 0.91, 95% CI: 0.79-1.06, p = 0.217) the lockdown. These findings remained stable when separately analyzing the implementation of patients with HIV (n = 61), DKD (n = 25) or MLTD (n = 22). Too few patients with cancer were included (n = 10) to interpret the results. In 2019, the implementation of 61/118 (51.7%) patients was significantly lower during summertime versus wintertime (OR = 0.73, 95% CI: 0.60-0.89, p = 0.002).
Medication implementation remained steady before, during and after the lockdown in 2020. The IMAP before, during and after the lockdown may have supported the adherence of most patients, by ensuring continuity of care during periods of routine disturbances.
Mots-clé
COVID-19, SARS-CoV-2, electronic adherence monitoring, implementation adherence, interprofessional adherence intervention, medication adherence, patient compliance
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/09/2022 9:16
Dernière modification de la notice
09/03/2023 7:50
Données d'usage